MannKind

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Bruker (BRKR) and BrightSpring Health Services, Inc. (BTSG)
  TipRanks · 2026/7/27
• H.C. Wainwright Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $10
  Market Newswire · 2026/9/22
• Rating change
  A Quick Look at Today's Ratings for MannKind(MNKD.US), With a Forecast Between $4.75 to $10
  Market Newswire · 2026/5/8
• Company notice
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/9/29
• Truist Financial Maintains MannKind(MNKD.US) With Buy Rating, Announces Target Price $6
  Market Newswire · 2026/10/1
• Rating change
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $13
  Market Newswire · 2026/9/2
• Company notice
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/5/14
• Company notice
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/5/23
• Rating change
  Cantor Fitzgerald Maintains MannKind(MNKD.US) With Buy Rating, Cuts Target Price to $8
  Market Newswire · 2026/8/6
• Rating change
  Wedbush Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $8
  Market Newswire · 2026/7/30
• H.C. Wainwright Keeps Their Buy Rating on MannKind (MNKD)
  TipRanks · 2026/9/22
• Rating change
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $11
  Market Newswire · 2026/6/3
• Truist Financial Maintains MannKind(MNKD.US) With Buy Rating
  Market Newswire · 2026/9/10
• Company notice
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/9/15
• Company notice
  4: MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/7/18
• Rating change
  A Quick Look at Today's Ratings for MannKind(MNKD.US), With a Forecast Between $4.75 to $13
  Market Newswire · 2026/8/6
• Rating change
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Raises Target Price to $14
  Market Newswire · 2026/7/30
• Rating change
  RBC Capital Maintains MannKind(MNKD.US) With Hold Rating, Maintains Target Price $4.75
  Market Newswire · 2026/7/27
• Rating change
  Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)
  TipRanks · 2026/5/28
• Cantor Fitzgerald Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $8
  Market Newswire · 2026/9/11

Headlines are aggregated automatically and are not independently verified or edited by our team.